found in both pancreatic sufficient and insufficient patients.' 5 The Rl 066C mutation was found in a CF carrier with bronchiectasis.2 All these reports referred to subjects who were heterozygous for the R1066 hot spot mutations. Thus, our patient with homozygous R1066C presents the opportunity to investigate the phenotype of this mutation. The patient is the product of a consanguineous mating between first cousins. Her parents were from Arecibo in Puerto Rico. She was diagnosed at 1 year of age because of failure to thrive and recurrent pneumonia. Sweat chloride was 106 mEq/l. During her childhood, the patient claimed to take enzymes, and maintained low to normal levels of vitamins, cholesterol, and albumin. There was no significant change after withdrawal of enzyme therapy at the age of 16. Despite her bronchiectasis, she was extremely active in sports and noted little impairment in her lung function. At the age of 20, she gave birth to a healthy daughter, who continues to be in good health. During her late 20s, the patient began to have frequent episodes of bronchitis that required antibiotic treatment. At the age of 30, a positive culture was obtained for Aspergillus fumigatus. At the age of 31, she sustained a spinal injury in a serious car accident, was unable to breathe because of the back pain, and developed a severe pneumonia. Her lung function then deteriorated rapidly. At the age of 32, her pulmonary function was extremely poor. The peak flow, FEV, and FVC were 30%, 26%, and 32% of predicted, respectively. The difference in pulmonary function obtained before and after administration of the meter dose inhaler was not significant. The patient was colonised with Pseudomonas aerugenosa that were not multiply resistant. The patient died at the age of 36 from respiratory failure compounded by malnutrition. Before death she weighed 32 kg, was 147 cm tall, and had become diabetic. Since fewer than 5% of currently surviving CF patients exceed the age of 36, her clinical course can be characterised as moderate.
Mutations in the CFTR gene of this patient were originally studied by a commercial laboratory. None of the 34 point mutations analysed was detected. This patient's mutant CF alleles were identified by single strand conformational polymorphism (SSCP) analysis of the polymerase chain reaction product of exon 17b6 followed by direct DNA sequencing and confirmatory allele specific oligonucleotide (ASO) hybridisation. Neither of her parents was available for DNA testing. In order to eliminate the possibility that the apparent homozygosity is the result of amplifying only one allele, additional primers were used to show that the absence of the normal allele is not the result of mutations at the primer binding sites. No other mutations were detected by SSCP screening of 16 exons (exons 3, 4, 5, 6a, 7, 9, 10, 11, 12, 13a, 13b, 15, 17b, 19, 20, 21) in the CFTR gene. Since the R1066C is a rare mutation and the patient is the product of a consanguineous mating, we conclude that the patient is homozygous for the R1066C mutation.
The R1066C missense mutation is relatively uncommon in white populations, occurring with a frequency of 0.3% in the German population.7 It is more common in people of Spanish descent with a frequency of 0.72%,' and has an unusually high frequency of 4.8% in CF patients from Portugal.9 Reviewing the point mutations that were analysed by several well known commercial laboratories in the United States, we found that the R1066 mutation hot spot was not included in any of the mutation panels screened. We recommend that the R1066 mutation hot spot be analysed, especially if the patients are of Spanish, Portuguese, or Hispanic origin.
All reported R1066C cases were heterozygous, and most of the clinical courses were not described except one compound heterozygous carrier, with a rare DNA polymorphism, whose major clinical manifestation was disseminated bronchiectasis. In this latter report, the results indicated that disseminated bronchiectasis of unknown origin is frequently associated with CFTR gene mutations or rare DNA polymorphisms. Our patient, homozygous for mutation R1066C, had a classical presentation of CF. During the course of screening 16 exons, including part of the flanking intron sequences, we discovered three polymorphisms. Two of them, 875+40 A-G in intron 6a and 3601-65 C-A in intron 18, have been previously reported.'" The other one, which has not been reported, is 622-58 T-G in intron 4. It is unclear at the present time if these polymorphisms have any clinical significance.
The substitution of a cysteine residue for arginine could potentially be a severe mutation since these two amino acids are structurally and electrochemically distinct. However, R1066 is located at the cytoplasmic loop between the fourth and fifth transmembrane segments of the second membrane spanning 
Lack of evidence for genetic heterogeneity in Best vitelliform macular dystrophy
We have previously presented data suggesting that the VMD2 disease locus in the pericentromeric region of chromosome 11 may be excluded in a small German kindred (family E) segregating Best's disease. We ran a multipoint linkage analysis, using markers D1 1S905, D1lS1355, D1lS903, D1 S986, and D 1S11357 that excluded in excess of 10 cM on either side of these markers.' Given the estimate that the critical region was between Dl 1S903 and PYGM, and approximated 3.7 cM in distance,2 we suggested that the data provided evidence for genetic heterogeneity in this disorder. However, it has been suggested that, as the markers used all map to the centromeric side of the VMD2 disease locus, and that estimates of the extent of the VMD2 critical region differ,3 some doubt would still exist as to whether or not there is substantive evidence for genetic heterogeneity.4 We used markers known to be on both sides of the disease locus to run a multipoint analysis in the family. Accurate distances between these markers were determined by the construction of a detailed map of the region (fig 1) . Multipoint linkage analysis using markers 1 lp-Dl 1S903-Dl1 S1357-Dl1S4191-Dl lS1883-PYGMDl1S1889-1 lq excluded a region between D 1I S903 and PYGM. However, haplotype analysis showed that exclusions on the 11 q distal side of the disease locus were based on two unaffected subjects who shared the same haplotype as all the affected members of the family. Clinical reassessment resulted in the rediagnosis of one of these as affected. Figure 1 Diagram of a linkage map of microsatellite markers in the region of the VMD2 disease locus. This map was created using CRI-MAP version 2.46. Genotype data used to create this map was downloadedfrom the CEPH database, converted to CRI-MAPformat using MAP+ 7, and merged with data from markers run through families E and BTMD1 (a second, largerfamily segregating Best's disease). Uniquely placed markers are indicated by underlining and are given code numbers from I to 22. Markers indistinguishable by recombination from just one other locus are placed beside it and are assumed to occupy roughly the same position. Markers indistinguishable by ,recombination from a number of uniquely placed loci are indicated beside arrows. The arrows define the interval between which the non-uniquely placed marker or markers beside and to the right hand side of the arrow in question can be found. Numbers at either end of the arrows indicate the closest uniquely placed markers distinguishable by recombination from the markers beside the arrows. (For example, D 1S987 is located somewhere between markers 16 and 19 (PYGM and D 1S916).) Sex averaged and sex specific centimorgan values for the genetic distances between the uniquely placed markers are given to the extreme left of the diagram.
